Abd El-Hameed Abeer M, Eskandrani Areej A, Salah Abdel-Reheim Eman, Abdel Moneim Adel, Addaleel Wessam
Chemistry Department, Faculty of Science, Taibah University, Saudi Arabia.
Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University, Egypt.
Saudi Pharm J. 2024 May;32(5):102029. doi: 10.1016/j.jsps.2024.102029. Epub 2024 Mar 13.
Inflammation is a condition that is closely linked to diabetes mellitus type 2 (T2DM), short for T2DM several different antidiabetic medications have been produced to regulate hyperglycemia, with indications that these therapies may have anti-inflammatory effects along with their glucose-lowering efficacy. Thus, this research was planned to explore the impact of antidiabetic agents on the cytokine expression levels -interleukin (IL)-1β, IL-6, IL-17, and IL-37 when patients have T2DM. In this study, 168 eligible subject matter was split into two groups: 50 healthy individuals and 118 cases with T2DM, who were classified into two subgroups: 30 untreated patients and 88 patients treated with metformin-based therapy. The outcome exhibited a significant increase within HbA1c% and proinflammatory cytokines (i.e., IL-1β, IL- 6, and IL-17), whereas IL-37 decreased considerably in untreated cases with T2DM compared to those in subjects who are healthy. Furthermore, the results showed increased levels Regarding waist size, body mass index and assessment using that homeostasis model, cholesterol, triglycerides, low-density lipoprotein levels, and heart danger elements in untreated cases with T2DM in comparison with hygienic subjects. Notably, treated patients with T2DM revealed an ameliorative impact on HbA1c, IL-6, IL-17, IL-37, IL-1β levels and lipid profile compared with untreated patients with T2DM. Antidiabetic agents may have a beneficial activity on the inflammatory status by reducing blood glucose levels, hyperlipidemia, and proinflammatory cytokines. The anti-inflammatory activity of IL-37 can apply a potentially effective therapeutic goal in treating T2DM and its complications.
炎症是一种与2型糖尿病（T2DM）密切相关的病症，针对T2DM已研发出多种不同的抗糖尿病药物来调节高血糖，有迹象表明这些疗法在降低血糖功效的同时可能还具有抗炎作用。因此，本研究旨在探讨抗糖尿病药物对T2DM患者细胞因子表达水平——白细胞介素（IL）-1β、IL-6、IL-17和IL-37的影响。在本研究中，168名符合条件的受试者被分为两组：50名健康个体和118例T2DM患者，后者又被分为两个亚组：30例未治疗患者和88例接受基于二甲双胍治疗的患者。结果显示，与健康受试者相比，未治疗的T2DM患者的糖化血红蛋白百分比（HbA1c%）和促炎细胞因子（即IL-1β、IL-6和IL-17）显著升高，而IL-37则大幅下降。此外，结果还显示与健康受试者相比，未治疗的T2DM患者在腰围、体重指数以及采用稳态模型评估时的胆固醇、甘油三酯、低密度脂蛋白水平和心脏危险因素方面均有所升高。值得注意的是，与未治疗的T2DM患者相比，接受治疗的T2DM患者在HbA1c、IL-6、IL-17、IL-37、IL-1β水平和血脂谱方面有改善作用。抗糖尿病药物可能通过降低血糖水平、高脂血症和促炎细胞因子对炎症状态产生有益作用。IL-37的抗炎活性可能为治疗T2DM及其并发症提供一个潜在有效的治疗靶点。
